Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 7,595 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Bones Clear all

Conditions: Myelodysplastic Syndrome(MDS), Acute Myelogenous Leukemia (AML)
Interventions: Nadunolimab, Azacitidine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: nilotinib, cytogenetic analysis, mutation analysis, polymerase chain reaction, pharmacological study; Drug · Genetic · Other
Lead sponsor: Cancer Trials Ireland; Network
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: HIV Infections
Interventions: Subjects do not receive study medication in this study 202094; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: Joint Disease
Interventions: Not listed
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 1
States / cities: Rochester Hills, Michigan

Conditions: Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Avascular Necrosis
Interventions: Alumina/Alumina, Standard; Device
Lead sponsor: Encore Medical, L.P.; Industry
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 3
States / cities: Newport Beach, California • Charleston, South Carolina • Richmond, Virginia

Conditions: Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma
Interventions: Fine-Needle Aspiration, Irinotecan, Irinotecan Hydrochloride, Lurbinectedin; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: AML, ALL, Blast Crisis, MDS, Multiple Myeloma
Interventions: TG02 citrate, Carfilzomib, Dexamethasone; Drug
Lead sponsor: Tragara Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 9
States / cities: Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: Rhizomelic Chondrodysplasia Punctata
Interventions: Not listed
Lead sponsor: MED-LIFE DISCOVERIES LP; Industry
Eligibility: 6 Months to 21 Years
Enrollment: 75 participants
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Degenerative Disc Disease, Scoliosis
Interventions: Oblique Lateral Interbody Fusion; Procedure
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Murrieta, California • San Francisco, California • Melbourne, Florida + 3 more

Conditions: B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
Interventions: nilotinib, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, methotrexate, cytarabine, prednisone, mesna, dexamethasone, leucovorin calcium; Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Solid Tumors, CNS Tumors
Interventions: Entrectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 15
States / cities: La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Acute Myocardial Infarction
Interventions: Autologous, Unfractionated Bone Marrow Mononuclear Cells; Drug
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 21 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Anterior Cruciate Ligament Rupture
Interventions: Fertilized ACL; Procedure
Lead sponsor: Marshall University; Other
Eligibility: 14 Years to 26 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Huntington, West Virginia

Conditions: Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
Interventions: Tissue specimen collection, MRI; Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 70 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1997
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Disorders
Interventions: ARA C, Cyclophosphamide, MESNA, Total Body Irradiation (TBI), Campath-1h, Stem Cell Infusion; Drug · Radiation · Biological + 1 more
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tumor Lysis Syndrome
Interventions: As Needed Rasburicase, Fixed Dose Rasburicase; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: bleomycin sulfate, recombinant interferon alfa, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methotrexate, prednisone, vincristine sulfate, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 15 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2011
U.S. locations: 86
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more

Conditions: Osteomyelitis, Diabetic Foot Osteomyelitis
Interventions: Bacteriophage Therapy, Placebo; Biological · Other
Lead sponsor: Adaptive Phage Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Tuscon, Arizona • Fairfield, California • Torrance, California + 11 more

Conditions: Severe Aplastic Anemia
Interventions: Antithymocyte Globulin (ATG), Fludarabine, Cyclophosphamide, Total Body Irradiation (TBI), Haplo HSCT, Tacrolimus, Mycophenolate mofetil (MMF), G-CSF; Drug · Radiation · Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 28
States / cities: Duarte, California • Los Angeles, California • Oakland, California + 24 more

Conditions: Hodgkin Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma
Interventions: lopinavir, ritonavir, polymerase chain reaction, flow cytometry, enzyme-linked immunosorbent assay, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Clofarabine, Cytarabine, Decitabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Exercise, Bone Resorption, Bone Formation
Interventions: Endurance exercise intervention; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 25 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Spinal Fusion Acquired, Spinal Stenosis, Lesions of Lumbosacral Intervertebral Disc, Spinal Diseases
Interventions: Dexmedetomidine, 0.9% Saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 2
Interventions: Avandamet 6 mg/1500 mg (ttd), Avandamet 4 mg/1000 mg (ttd), Avandamet 2 mg/500 mg (ttd), Avandamet 8 mg/ 2000 mg (ttd), Metformin 500 mg (ttd), Metformin 1000 mg (ttd), Metformin 1500 mg (ttd), Metformin 2000 mg (ttd); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 71
States / cities: Tuscaloosa, Alabama • Gilbert, Arizona • Glendale, Arizona + 65 more

Search by objective public record fields.

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

Microplasty Tibial Tray Data Collection

Cementless Alumina-Alumina Total Hip and Hybrid

Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

RCDP Natural History Study

OLIF25™ /OLIF51™ Study

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Bone Marrow Stem Cell Infusion Following a Heart Attack

Return to Play After ACL Reconstruction With Bone Marrow Aspirate, DBM, and an Internal Brace

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

T-Reg Cell Kinetics, Stem Cell Transplant, REGALE

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Enhancing Skeletal Adaptations to PTH and Exercise

Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion

A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin